Targeted chemotherapy overcomes drug resistance in melanoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Drug resistance is a significant challenge in melanoma treatment.
• Conventional chemotherapy is often ineffective against resistant melanoma cells that enter dormancy.
• Targeted therapies can also face emerging resistance.

Purpose of the Study:

• To introduce a novel therapeutic strategy called "targeted chemotherapy" for drug-resistant melanoma.
• To investigate the efficacy of inhibiting protein phosphatase 2A (PP2A) using phendione in melanoma.
• To assess the potential of this strategy in overcoming existing resistance and preventing new resistance.

Main Methods:

• Depletion or inhibition of protein phosphatase 2A (PP2A) using the small molecule inhibitor 1,10-phenanthroline-5,6-dione (phendione).
• Treatment of drug-resistant melanoma models, including patient-derived xenografts (PDX) with specific mutations (BRAF^V600E, NRAS^Q61R).
• Evaluation of DNA damage response induction, cellular dormancy, and tumor growth inhibition.

Main Results:

• Targeted chemotherapy with phendione induced a DNA damage response without causing DNA breaks or cellular dormancy.
• Phendione treatment significantly reduced tumor growth in BRAF^V600E-driven melanoma PDX models.
• Phendione diminished tumor growth in NRAS^Q61R-driven melanoma, a cancer lacking effective therapies.
• Phendione treatment prevented the development of resistance to BRAF inhibition in relevant models.

Conclusions:

• Targeted chemotherapy by inhibiting PP2A with phendione is a promising strategy for overcoming drug resistance in melanoma.
• This approach is effective against both BRAF-mutant and NRAS-mutant melanoma, including resistant forms.
• Phendione shows potential in preventing the emergence of resistance to targeted therapies, offering a new avenue for melanoma treatment.